Primary HPV Testing vs Co-testing for Cervical Cancer Screening
This article provides foundational evidence demonstrating the diagnostic superiority of co-testing compared with primary high-risk HPV testing alone (HPV testing).
Outcome and Economics Support that Co-testing is Superior
In 2014, the FDA approved a DNA HPV test for primary cervical cancer screening in women 25 years and older. This article provides foundational evidence demonstrating the diagnostic superiority of co-testing compared with primary high-risk HPV testing alone (HPV testing). Using an extensive modeling analysis, a screening span of up to 40 years, and a constructed cohort of 1 million women, we predicted that co-testing would result in thousands of fewer invasive cervical cancer cases and deaths and would save the healthcare system $39 million over the 40 years, as compared to a strategy using primary HPV testing alone. These findings are not only relevant when considering Women’s Healthcare policies, but they also direct attention to real-world outcomes and economics critical to selecting the best strategies for cervical cancer screening.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.